[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558754":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":44,"responsibleParty":66,"collaborators":26,"id":68,"slug":26,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":47,"whyStopped":26,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Medical University of Warsaw","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Trametynib","EXPERIMENTAL","Trametynib in 0,025mg\u002Fkg dose orally once daily",[13],"Drug: Trametinib tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard therapy","ACTIVE_COMPARATOR","Disopiramide and Beta-blocker orally",[19],"Drug: Standard therapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Trametinib tablet","Trametynib orally once daily in 0,025mg\u002Fkg dose",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Disopiramide and Beta blockers orally",[15],[31],{"name":32,"affiliation":5,"role":33},"MAciej Kołodziej, MD","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":26,"email":39},"Maciej Kołodziej, MD","CONTACT","22-317-95-37","maciej.kolodziej@wum.edu.pl",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},"Halszka Kamińska, MD","22-317-9444","halszka.kaminska@wum.edu.pl",[45],{"facility":46,"status":47,"city":48,"state":26,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Department of Paediatrics, The Medical University of Warsaw, Poland","RECRUITING","Warsaw","02-091","Poland",{"type":52,"coordinates":53},"Point",[54,55],21.01178,52.22977,{"lat":55,"lon":54},[58,61,62,63],{"name":36,"role":37,"phone":59,"phoneExt":26,"email":60},"223179535","maciek.kolodziej@gmail.com",{"name":41,"role":37,"phone":42,"phoneExt":26,"email":43},{"name":36,"role":33,"phone":26,"phoneExt":26,"email":26},{"name":64,"role":65,"phone":26,"phoneExt":26,"email":26},"Hlaszka Kamińskia, MD","SUB_INVESTIGATOR",{"type":67,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100558754",false,"NCT06555237","MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies","MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies (MEKinRAS) - Randomized Controlled Trial","MEKinRAS","Inclusion Criteria:\n\n* patient with diagnosed RASopathy\n* patient with diagnosed hypertrophic cardiomyopathy\n* signed innform consent\n\nExclusion Criteria:\n\n* contraindications to treatment with propranolol (drug hypersensitivity, atrioventricular block, severe bradycardia) disopyramide (drug hypersensitivity, WPW syndrome, atrioventricular block, QT prolongation) trametinib (drug hypersensitivity)\n* lack of consent of the child's guardians to participate in the study","ALL","1 Day","18 Years",{"count":79,"type":80},40,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS\u002FMAPK pathway.",[86,87],"Cardiomegaly","Noonan Syndrome",[89,90,91,92,93],"Noonan syndrome","MEK kinase","RASOpathies","Children","Cardiomyopathy","2024-08-12",{"date":96,"type":97},"2024-08-15","ACTUAL",{"date":99,"type":97},"2024-08-01",{"date":101,"type":80},"2026-12-01",{"name":5,"class":6},1]